{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T18:06:55Z","timestamp":1774634815033,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.eprac.2024.10.008","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T07:31:23Z","timestamp":1729582283000},"page":"42-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Temozolomide Therapy in Management of Refractory Pituitary Adenomas: A Case Series of 39 Patients"],"prefix":"10.1016","volume":"31","author":[{"given":"Xiaohai","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congxin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2905-5119","authenticated-orcid":false,"given":"Chenxin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinjie","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingchu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eprac.2024.10.008_bib1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.eprac.2024.10.008_bib2","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1210\/jc.2010-1048","article-title":"Pituitary incidentaloma: an endocrine society clinical practice guideline","volume":"96","author":"Freda","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2024.10.008_bib3","series-title":"StatPearls","article-title":"Pituitary adenoma","author":"Russ","year":"2024"},{"issue":"10","key":"10.1016\/j.eprac.2024.10.008_bib4","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1517\/14656566.2011.568478","article-title":"Therapy of aggressive pituitary tumors","volume":"12","author":"Colao","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.eprac.2024.10.008_bib5","article-title":"The clinical and pathological characteristics of refractory pituitary adenomas: a single center experience","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.eprac.2024.10.008_bib6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3389\/fendo.2019.00334","article-title":"The treatment of refractory pituitary adenomas","volume":"10","author":"Dai","year":"2019","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2024.10.008_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000371806","article-title":"Aggressive pituitary tumors","volume":"101","author":"Chatzellis","year":"2015","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/j.eprac.2024.10.008_bib8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11102-018-0868-4","article-title":"Management of nonfunctioning pituitary tumors: radiotherapy","volume":"21","author":"Minniti","year":"2018","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.eprac.2024.10.008_bib9","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/cncr.22860","article-title":"The efficacy of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas: long-term results of 125 consecutive patients treated in a single institution","volume":"110","author":"Kong","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.eprac.2024.10.008_bib10","first-page":"621","article-title":"Long-term response of pituitary carcinoma to temozolomide. Report of two cases","volume":"105","author":"Fadul","year":"2006","journal-title":"J\u00a0Neurosurg"},{"issue":"6","key":"10.1016\/j.eprac.2024.10.008_bib11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(06)70728-8","article-title":"Temozolomide: a novel treatment for pituitary carcinoma","volume":"7","author":"Lim","year":"2006","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.eprac.2024.10.008_bib12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11060-015-1991-y","article-title":"Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas","volume":"126","author":"Losa","year":"2016","journal-title":"J\u00a0Neuro Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2024.10.008_bib13","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2024.10.008_bib14","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1530\/EJE-16-0979","article-title":"Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas","volume":"176","author":"Lasolle","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2024.10.008_bib15","first-page":"188","article-title":"Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports","volume":"3","author":"Ji","year":"2016","journal-title":"Neurooncol Pract"},{"issue":"3","key":"10.1016\/j.eprac.2024.10.008_bib16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11102-023-01320-9","article-title":"Medical therapy for refractory pituitary adenomas","volume":"26","author":"Geer","year":"2023","journal-title":"Pituitary"},{"issue":"12","key":"10.1016\/j.eprac.2024.10.008_bib17","doi-asserted-by":"crossref","first-page":"966","DOI":"10.2176\/nmc.ra.2014-0178","article-title":"Treatment of pituitary carcinomas and atypical pituitary adenomas: a review","volume":"54","author":"Hirohata","year":"2014","journal-title":"Neurol Med -Chir"},{"key":"10.1016\/j.eprac.2024.10.008_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.616339","article-title":"Case report: temozolomide treatment of refractory prolactinoma resistant to dopamine agonists","volume":"12","author":"Tang","year":"2021","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2024.10.008_bib19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016","volume":"178","author":"McCormack","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2024.10.008_bib20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"Burman","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2024.10.008_bib21","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1210\/jc.2014-4350","article-title":"Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide","volume":"100","author":"Bengtsson","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2024.10.008_bib22","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/s41467-024-45979-5","article-title":"Trans-lesion synthesis and mismatch repair pathway crosstalk defines chemoresistance and hypermutation mechanisms in glioblastoma","volume":"15","author":"Cheng","year":"2024","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.eprac.2024.10.008_bib23","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/ijc.28199","article-title":"Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways","volume":"133","author":"Dai","year":"2013","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2024.10.008_bib24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"4","key":"10.1016\/j.eprac.2024.10.008_bib25","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.21037\/gs-20-873","article-title":"Diagnosis and treatment of refractory pituitary adenomas: a narrative review","volume":"10","author":"Liu","year":"2021","journal-title":"Gland Surg"},{"issue":"6","key":"10.1016\/j.eprac.2024.10.008_bib26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","article-title":"Clinical biology of the pituitary adenoma","volume":"43","author":"Melmed","year":"2022","journal-title":"Endocr Rev"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2024.10.008_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.6061\/clinics\/2012(Sup01)20","article-title":"Temozolomide in aggressive pituitary adenomas and carcinomas","volume":"67","author":"Ortiz","year":"2012","journal-title":"Clinics"},{"issue":"4","key":"10.1016\/j.eprac.2024.10.008_bib28","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1365-2265.2006.02630.x","article-title":"Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study","volume":"65","author":"Filippella","year":"2006","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2024.10.008_bib29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s42000-019-00145-1","article-title":"Is MGMT the best marker to predict response of temozolomide in aggressive pituitary tumors? Alternative markers and prospective treatment modalities","volume":"18","author":"Kontogeorgos","year":"2019","journal-title":"Hormones (Basel)"},{"issue":"2","key":"10.1016\/j.eprac.2024.10.008_bib30","first-page":"261","article-title":"MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy","volume":"115","author":"Kovacs","year":"2008","journal-title":"Acta\u00a0Neuropathol"},{"issue":"5","key":"10.1016\/j.eprac.2024.10.008_bib31","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.trecan.2020.02.010","article-title":"MGMT status as a clinical biomarker in glioblastoma","volume":"6","author":"Butler","year":"2020","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2024.10.008_bib32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3892\/ol.2017.6123","article-title":"Relationship between MGMT gene expression and treatment effectiveness and prognosis in glioma","volume":"14","author":"Li","year":"2017","journal-title":"Oncol Lett"},{"issue":"6","key":"10.1016\/j.eprac.2024.10.008_bib33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ccr.2006.05.013","article-title":"Mismatch repair proteins as sensors of alkylation DNA damage","volume":"9","author":"Wang","year":"2006","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.eprac.2024.10.008_bib34","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-10-0821","article-title":"Therapeutic targeting of the DNA mismatch repair pathway","volume":"16","author":"Martin","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.eprac.2024.10.008_bib35","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1158\/1078-0432.CCR-08-3012","article-title":"MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance","volume":"15","author":"Yip","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.eprac.2024.10.008_bib36","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1210\/jc.2012-2924","article-title":"DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the National Cooperative study by the Japan society for hypothalamic and pituitary tumors","volume":"98","author":"Hirohata","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T02:01:50Z","timestamp":1736301710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24008012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1530891X24008012"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.10.008","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temozolomide Therapy in Management of Refractory Pituitary Adenomas: A Case Series of 39 Patients","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}